Mutation News and Research

RSS

Researchers identify biological process that appears to trigger Parkinson's disease

Working with human neurons and fruit flies, researchers at Johns Hopkins have identified and then shut down a biological process that appears to trigger a particular form of Parkinson's disease present in a large number of patients. A report on the study, in the April 10 issue of the journal Cell, could lead to new treatments for this disorder.

11 Apr 2014

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Cardiovascular Institute are among the 2014 recipients of the prestigious Clinical Research Achievement Award for their work in cardiovascular science.

11 Apr 2014

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.

11 Apr 2014

Scientists discover potential cause of Parkinson’s disease

Researchers have discovered a process that appears to explain how a well known enzyme mutation triggers the neural deterioration seen in Parkinson’s disease.

10 Apr 2014

Comprehensive genomic analysis of low-grade brain tumors sorts into three categories

Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors, researchers reported at the American Association for Cancer Research Annual Meeting 2014.

10 Apr 2014

Researchers find that cancer gene require copper to promote tumor growth

Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report.

10 Apr 2014

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Wednesday, April 9, 2014 at the American Association of Cancer Researchers conference in San Diego, CA.

10 Apr 2014

Study shows dabrafenib has no added benefit in comparison with dacarbazine

Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) had determined that dabrafenib has no added benefit in comparison with dacarbazine.

10 Apr 2014

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

9 Apr 2014

Scientists uncover surprising link between brain development and gene tied to breast cancer

Scientists at the Salk Institute have uncovered details into a surprising-and crucial-link between brain development and a gene whose mutation is tied to breast and ovarian cancer.

9 Apr 2014

Study shows subpopulations of breast cancer cells cooperate to aid tumor growth

Subpopulations of breast cancer cells sometimes cooperate to aid tumor growth, according to Penn State College of Medicine researchers, who believe that understanding the relationship between cancer subpopulations could lead to new targets for cancer treatment.

9 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

Biologists find ways to address antibiotic resistance

Biologists could gain a deeper understanding about how species have evolved - and even find ways to address antibiotic resistance - using tools that were developed recently at Stockholm's KTH Royal Institute of Technology.

8 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

Novartis Institute researcher receives second annual Andrew Carnegie Prize in Mind and Brain Sciences

Carnegie Mellon University will award the second annual Andrew Carnegie Prize in Mind and Brain Sciences to Ricardo Dolmetsch, global head of neuroscience at the Novartis Institute for Biomedical Research.

8 Apr 2014

Dream team aims to turn pancreatic cancer into treatable disease

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer.

8 Apr 2014

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment.

8 Apr 2014

Study examines links between parental obesity and risk of autism developmental in child

Several studies have looked at possible links between maternal obesity during pregnancy and the risk of developmental disorders in the child. However, paternal obesity could be a greater risk factor than maternal obesity, according to a new study from the Norwegian Institute of Public Health.

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Mutation News and Research

Researchers identify biological process that appears to trigger Parkinson's disease

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Scientists discover potential cause of Parkinson’s disease

Comprehensive genomic analysis of low-grade brain tumors sorts into three categories

Researchers find that cancer gene require copper to promote tumor growth

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Study shows dabrafenib has no added benefit in comparison with dacarbazine

Researchers identify experimental drugs to block treatment-resistant leukemia

Scientists uncover surprising link between brain development and gene tied to breast cancer

Study shows subpopulations of breast cancer cells cooperate to aid tumor growth

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Biologists find ways to address antibiotic resistance

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Novartis Institute researcher receives second annual Andrew Carnegie Prize in Mind and Brain Sciences

Dream team aims to turn pancreatic cancer into treatable disease

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Study examines links between parental obesity and risk of autism developmental in child

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News